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DOI 10.1016/j.cell.2011.03.026Building on years of basic scientific discovery, recent advances in the fields of cancer genetics and
medicinal chemistry are now converging to revolutionize the treatment of cancer. Starting with
serendipitous observations in rare subsets of cancer, a paradigm shift in clinical research is poised
to ensure that new molecular insights are rapidly applied to shape emerging cancer therapies.
Could this mark a turning point in the ‘‘War on Cancer’’?In the past year, a startling series of clinical
studies has brought molecularly targeted
therapies to the treatment of diverse
cancers. An inhibitor that blocks a specific
mutant of the serine/threonine kinase
B-RAF (V600E-B-RAF) demonstrated
dramatic efficacy in treating metastatic
melanoma, a cancer that was long thought
to be among the most refractory (Flaherty
et al., 2010). An inhibitor of the anaplastic
lymphoma kinase (ALK) proved highly
effective against a subset of nonsmall cell
lung cancers that had been prescreened
for an oncogenic EML4-ALK translocation
(Kwak et al., 2010). A Janus kinase 2
(JAK2) inhibitor proved beneficial against
a form of preleukemia, myelodysplastic
syndrome, that harbors an activating
JAK2 mutation (Verstovsek et al., 2010). In
B cell hematological malignancies, which
selectivelyexpress theclass Iphosphatidy-
linositol 3-kinase (PI3K) d isoform, a PI3K
d-specific inhibitor has shown remarkable
activity in refractory tumors (Furman et al.,
2010). Even the immunology front, after
years of setbacks, made significant strides
whenantibodiesabrogatinganticytotoxicT
lymphocyte antigen (CTLA)-4 improved
survival in patients with advanced mela-
noma (O’Day et al., 2010). In addition,
we anticipate promising results from
approaches that combine known treat-
ments, such as using both mitogen-acti-
vated protein kinase kinase (MEK) and
PI3K inhibitors to treat cancers with muta-
tions in K-RAS (Engelman et al., 2008)
and combining antibodies and kinase
inhibitors to treat breast cancers with the
HER2 gene amplified (Baselga et al., 2010).Most impressive, however, is the sense
that the timeline of translating molecular
studies into the clinic is accelerating. For
example, it took 6–8 years to demonstrate
the efficacy of B-RAF and epidermal
growth factor receptor (EGFR) inhibitors
in appropriate clinical studies (Davies
et al., 2002; Flaherty et al., 2010; Lynch
et al., 2004; Mok et al., 2009; Paez et al.,
2004). In contrast, it took just more than
1 year for researchers to demonstrate
clinical responses to ALK inhibition in
a cohort of genotyped patients, after the
initial discovery of the EML4-ALK translo-
cations in a subset of lung cancers (Soda
et al., 2007; Kwak et al., 2010).
In this Essay, we explore the important
advances in cancer genetics, medicinal
chemistry, and clinical strategies contrib-
uting to these recent successes and
enhanced pace. Then, we discuss the
key challenges and objectives for
continual success. Clearly, the future of
targeted therapies depends upon
a detailed understanding of the molecular
genetic abnormalities that drive different
subsets of cancer, a rich pipeline of prom-
ising compounds targeting such lesions,
and the appropriate use of companion
diagnostics, both to prescreen patients
that are likely to respond and to detect
early signs of either drug response or
acquired resistance.
Breaking the Cancer War Stalemate
The ‘‘War on Cancer,’’ now 40 years old,
has been declared a failure, both in the
medical literature (Bailar and Gornik,
1997) and in the general press (Leaf,Ce2004). In contrast to the marked success
of cholesterol-lowering drugs and antihy-
pertensives in reducing the risk of cardio-
vascular disease, the decline in cancer
mortality has been relatively modest.
This decrease has been attributed
primarily to screening for breast and colon
cancer and preventive measures, such as
a reduction in smoking and the declining
use of postmenopausal estrogen replace-
ment. Could the new forms of cancer
treatment provide hope for reduced
mortality? And what are the critical
components that are required to achieve
a sustained impact on the disease?
It is perhaps ironic that the bill signed by
President Richard M. Nixon in 1971,
which was ultimately labeled the War on
Cancer, triggered a massive investment
in basic science. The research was under-
taken with the assumption that unbiased
fundamental research would hold the
key to unlocking the secrets of cancer
cells, and indeed, our current knowledge
about cellular biology and molecular
genetics owes much to this national
investment.
Although the anticipated timeline for
clinical applications of basic research
may have been optimistic, recent
successes in targeted therapies are
based on the accumulated knowledge
generated by years of fundamental
research in genetics, signaling, cellular,
and molecular biology. In particular, we
have learned that the genesis of cancer
mirrors the process of mutation and
selection underlying our own evolution,
and the signals that drive or suppressll 145, April 1, 2011 ª2011 Elsevier Inc. 19
proliferation, apoptosis, differentiation,
and quiescence in cancer cells mimic
those of normal development.
We are finally capable of manipulating
these signals in some cancers to achieve
a profound initial response in the tumor.
However, the acquisition of resistance
by cancer cells prompts the need for
even greater understanding of cellular
mechanisms underlying cancer cells’
plasticity and adaptation. Single driving
genetic lesions may provide clear thera-
peutic targets in some cancers, but
a more profound understanding of inter-
connected signaling pathways may be
required to tackle the majority of tumors.
Drawing from Somatic Cancer
Genetics to Find Therapeutic
Targets
Early cancer genetic studies focused on
inherited cancer syndromes in which
a single germline mutation is responsible
for cancer susceptibility within a family.
Such studies provide clear and compel-
ling evidence for the one lesion, typically
in a tumor suppressor gene, that is
capable of initiating tumorigenesis, as
opposed to a vast number of somatic
aberrations accumulating during cancer
progression. Directed genotyping studies
uncovered additional somatic mutations,
chromosome translocations, and loss of
heterozygosity patterns, pointing to
recurrent (and hence probably significant)
lesions in many cancers. Functional
studies of introduced oncogenes and
tumor suppressor genes in cells and
model organisms readily demonstrated
the powerful impact of mutating a single
gene in triggering malignancy.
However, it was the decision to under-
take whole-scale sequencing of cancer
genomes, first by the Sanger Center and
then by US and international consortia,
that provided a comprehensive view of
somatic mutational landscapes in cancer
and potential therapeutic targets. Impor-
tant successes of genome-scale se-
quencing included the discovery of highly
recurrent and specific mutations in BRAF
and PI3K (Davies et al., 2002; Samuels
et al., 2004). However, most mutations
identified in such analyses appear to be
relatively rare and are not shared across
multiple cancers (Beroukhim et al.,
2010). Although such mutations may be
grouped within large functional pathways,20 Cell 145, April 1, 2011 ª2011 Elsevier Inc.predominant therapeutic targets have yet
to emerge for the majority of epithelial
cancers, which constitute 85% of all
cancers. Thus, although large cancer
genome sequencing projects are
underway formany different cancer types,
the identification of promising drug
targets may ultimately require detailed
biological insights to complement muta-
tional analyses.
Given that numerous mutations in
human cancers occur at low frequency,
it is essential to distinguish the mutations
that constitute essential ‘‘drivers’’ of
tumorigenesis from those that are
‘‘passengers’’ without functional signifi-
cance (for more on driver and passenger
mutations, see Ashworth et al., 2011 in
this issue). Of course, the response of
cancers to a targeted inhibitor is ulti-
mately the most compelling evidence for
the relevance of a given target. For
example, the dramatic clinical response
to EGFR inhibitors by patients whose
lung cancers harbor an activating EGFR
mutation clearly demonstrates that these
EGFR mutations are not simply
bystanders of mutational load, but rather
drivers of malignant proliferation (Lynch
et al., 2004; Paez et al., 2004). In fact,
the EGFR inhibitors trigger massive tumor
apoptosis in these lung cancers, suggest-
ing that these cells are ‘‘addicted’’ to the
EGFR signaling pathway for survival.
The concept of ‘‘oncogene addiction’’
emphasizes the critical role played by
the ‘‘wiring’’ of signaling pathways in
a cancer cell; specifically, a cancer cell’s
signaling networks may depend on
a single mutationally activated driving
pathway that, when disrupted, triggers
cell death (in effect, its ‘‘Achilles heel’’)
(Weinstein, 2002). However, identifying
such extraordinary drug targets and trans-
lating these into effective therapy is not
always straightforward, as illustrated by
the development of B-RAF inhibitors
against melanoma. The failure of sorafe-
nib, an inhibitor of B-RAF, in clinical trials
of metastatic melanoma challenged the
validity of V600E-B-RAF as a good drug
target until PLX4032, a more potent and
specific inhibitor against V600E B-RAF,
showed dramatic efficacy (Eisen et al.,
2006; Flaherty et al., 2010). It is in this
setting that preclinical modeling of onco-
gene addiction, using large panels of
cancer-derived cell lines, is emerging asan effective approach to validating both
target and inhibitor. Individual cell lines
have limited predictive value. However,
when they are studied in large aggregates,
they recapitulate much of the genetic
heterogeneity of human cancers, as well
as their specific hypersensitivity profiles
to inhibitors of EGFR, ALK, MET, FGFR,
and B-RAF (McDermott et al., 2007).
Preclinical efforts at target identification
and validation have also relied on
strategies that suppress gene expression
using interference RNA (RNAi), although
clinically validated targets have not
yet emerged from such genome-wide
screens. Instead of matching a single
compound against the entire genetic
heterogeneity of human cancers, RNAi
screens have typically focused on
screening the entire kinome against
a selected cell type. Important applica-
tions of this strategy include: searching
for new targets for which RNAi-induced
knockdown may reverse acquired resis-
tance to first-line targeted inhibitors, and
screens for ‘‘synthetic lethality,’’ in which
a target only becomes essential within
a specific genetic context (Berns et al.,
2004). For instance, the clinical effective-
ness of poly-ADP ribose polymerase
(PARP) inhibitors in breast and ovarian
cancers with BRCA gene mutations is
attributable to their inhibition of a parallel
DNA repair pathway that becomes critical
for cell viability only in the setting of BRCA
gene inactivation. Finally, both RNAi and
drug screens are essential to model effec-
tive combinations of agents required to
block interdependent cellular pathways
implicated in intrinsic and acquired drug
resistance. Drug resistance has been
attributed to numerous mechanisms,
including the appearance of additional or
‘‘second site’’ mutations within drug-
binding sites (Kobayashi et al., 2005; Pao
et al., 2005; Talpaz et al., 2006; Zhou
et al., 2009), the activation of parallel
signaling pathways (Engelman et al.,
2007), or even the induction of drug resis-
tance quiescence states (Sharma et al.,
2010). To counter all these mechanisms
requires an even better understanding of
the wiring diagram of cancer cells.
Challenging Medicinal Chemistry
to Design New Classes of Inhibitors
The history of targeted cancer therapy is
now intricately linked with the success of
imatinib (Gleevec) to treat chronicmyeloid
leukemia (CML). The prototype kinase
inhibitor imatinib blocks the ABL kinase,
which is activated in the BCR-ABL
chimeric fusion. From its first identifica-
tion as the Philadelphia chromosome
(Nowell and Hungerford, 1960) to its
molecular characterization as the sole
genetic driver of CML, BCR-ABL is the
perfect drug target (Druker, 2004). The
development of imatinib was the result
of a structure-activity relationship-guided
optimization of a phenylaminopyrimidine
lead compound that was originally identi-
fied as an inhibitor of protein kinase
C (Capdeville et al., 2002). Indeed, imati-
nib’s eventual application as a BCR-ABL
inhibitor owes much to serendipity, intui-
tion, and the dedication of individual
scientists.
The success of imatinib resolved
numerous concerns about using ATP-
mimics as kinase inhibitors. It demon-
strated that these inhibitors can compete
effectively for binding with the abundant
pool of cellular ATP and that they can
achieve selectivity despite closely related
catalytic pockets in other kinases. In addi-
tion, it proved that a class of signaling
molecules with broad expression patterns
in multiple normal tissues could indeed be
successful drug targets, given the excep-
tional sensitivity of genetically defined
subsets of cancer. Imatinib was initially
aimed at suppressing PDGFR signaling
that is implicated in the proliferation of
coronary endothelial cells; its fortuitous
‘‘off-target’’ effects on the ABL and c-KIT
kinases launched a revolution in cancer
therapy, and its anti-PDGFR effects ulti-
mately found their place in the treatment
of rare leukemias with PDGFR-dependent
translocations (Druker, 2004). The admit-
tedly serendipitous saga of imatinib
spawned a broad and systematic effort
throughout the pharmaceutical industry
that is now poised to radically change
the essential tools for cancer treatment.
Tremendous investment in medicinal
chemistry, primarily from the pharmaceu-
tical sector, has resulted in the develop-
ment of numerous efficient strategies for
designing potent and selective kinase
inhibitors. For example, PLX4720 was
developed by an innovative approach
called ‘‘fragment-based screening,’’ in
which small molecular fragments with
low affinity for V600E B-RAF were identi-fied and then optimized using rational
structure-guided drug design (Tsai et al.,
2008). In addition, structural biology of
kinases has become an integral part of
drug optimization, with large-scale initia-
tives such as the Structural Genomics
Consortium providing an increasingly
large fraction of new depositions (Mars-
den and Knapp, 2008).
Nonetheless, serendipity still plays
a major part in successful drug discovery.
For example, crizotinib was originally
designed as a c-MET inhibitor, but its
fortuitous off-target activity against ALK
drove its efficacy in EML4-ALK-depen-
dent lung cancer (Kwak et al., 2010).
Significant developmental hurdles still
exist for kinase inhibitors, including the
high interspecies variation in their toxic
side effects and the difficulty in decipher-
ing which of these are on-target versus
off-target effects of the inhibitor. Despite
their large investment, commercial enter-
prises have been reluctant to develop
inhibitors against kinases that have not
already been subject to intense biological
investigation. This has resulted in an
abundance of drugs against a relatively
small number of well-validated targets
but a dearth of inhibitors with sufficient
selectivity to validate the vast majority of
the kinome pharmacologically (Fedorov
et al., 2010). Although there are remark-
able examples of how broadly active
kinase inhibitors, such as sunitinib, may
be well tolerated, recent trends have
focused more on inhibition of specific
mutant targets. These include targeting
the specific B-RAFmutant V600E in mela-
noma, mutationally activated forms of
EGFR in lung cancer, and imatinib-resis-
tant T315I-BCR-ABL in CML (Flaherty
et al., 2010; Zhou et al., 2009).
Although many potential cancer thera-
pies remain in the pool of untargeted
kinases, new classes of cancer drugs on
the horizon are reaching outside of the
kinome to target modulators of protein
turnover and folding, phosphatases, chro-
matin-modifying enzymes, and regulators
of cellular metabolism. Transcription
factors andadaptor proteinswith relatively
large interaction surfaces remain a major
challenge for drug design. From a biolog-
ical standpoint, tumor suppressor genes,
which commonly sustain loss-of-function
mutations in cancer, are only druggable
through pathway components that displayCesynthetic lethality. Moreover, the most
commonvillains of cancer cells,mutations
in the oncogene K-RAS and the tumor
suppressor p53, have remained recalci-
trant to direct targeting approaches.
Manyof these targetswill require chemists
to invent entirely new classes of
compounds or develop novel approaches
for modulating their activity.
Targeted inhibitors stand to benefit
from integrated development within the
appropriate biological and genetic
contexts. Preclinical screens need to
test inhibition of an oncogenic target
within the appropriate cancer cells, in
which the targeted gene is biologically
relevant. When possible, biomarkers that
identify the responsive subset of cancers
should be selected during early preclinical
development, rather than awaiting retro-
spective analyses of clinical trials. As
with cancer cell line studies, animal
models used to optimize drug dosing
and toxicity profiles are most informative
if they recapitulate the genetic context of
the relevant subset of human cancer.
These approaches mark a departure
from classical drug testing paradigms
that have typically relied on testing a small
number of nonannotated cancer cell lines
and xenograft mouse models matched to
tissue type, rather than underlying genetic
lesion. However, the increasing cost of
testing large numbers of new agents that
may be highly selective for subsets of
cancer necessitates detailed information
to match the drug, disease subtype, and
biomarker before entry into clinical trials.
Redesigning Cancer Clinical Trials:
Genotype First, Monitor in Real
Time
There is a growing consensus that tradi-
tional designs of cancer clinical trial are
not well suited to address the current
needs of drug development. These clinical
trials typically begin with a phase one, in
which the maximally tolerated dose of
a new drug is defined by increasing
dosage in a small number of patients
(who have failed standard therapies and
are willing to be treated with a new
untested compound with uncertain bene-
fits). This is followed by a phase two trial in
a larger patient cohort with a specific
cancer type (without regard to the
cancer’s genotype or biomarkers); this
phase aims at defining efficacy at thell 145, April 1, 2011 ª2011 Elsevier Inc. 21
Figure 1. Matching Each Cancer with Individually Targeted Therapy: Steps toward Im-
plementing a New Clinical Strategy
In genotype-directed cancer therapy, the malignant tumor specimen is subjected to detailed biomarker
analysis, including immunohistochemical as well as DNA-based markers. These biomarkers are in-
terpreted within the relevant signaling pathway to identify a potential vulnerability for the cancer. Selection
of an appropriate therapy (often oral agents of limited toxicity) is dependent upon prior preclinical
validation of drug/genotype pairing and detailed analysis of drug/target interactions. Early drug response
and development of acquired resistance are monitored by repeat biopsy of the tumor or, noninvasively, by
functional imaging or circulating tumor cell analysis.appropriate drug dose. Eventually, if clin-
ical activity has been observed in the
phase two trial, a large randomized phase
three trial is conducted in which the new
drug, either alone or in combination with
currently used drugs, is directly compared
with the standard regimen. If successful,
phase three leads to FDA registration for
the new drug.
This strategy has resulted in a high
failure rate, and even in studies with
a positive outcome, the benefits are
mostly incremental in nonselected patient
populations. Besides time and expense,
the underlying premise of such trial
designs is not suited to the new world of
targeted cancer therapy. In particular,
defining the maximal tolerated dose for
selective inhibitors in patients whose
tumor does not carry biomarkers predic-
tive of response for that inhibitor is far
less relevant than preselecting tumors
that are likely to respond to the inhibitor
and defining the therapeutic index within
these relevant cases. Traditional multi-
institutional clinical trials have relied on
enrolling large numbers of unselected
patients, followed by retrospective anal-
ysis of tumor markers in a fraction of22 Cell 145, April 1, 2011 ª2011 Elsevier Inc.cases enrolled. Thus, they do not readily
lend themselves to detailed pretreatment
genotyping and may be underpowered
to assess drug effectiveness against rare
tumor subsets. Given the early and
dramatic responses in genotype-selected
cancers, the need and even the ethics of
large clinical trials—such as the one
randomizing V600E-positive melanoma
patients between highly effective
PLX4032 and minimally effective cyto-
toxic chemotherapy—is being vigorously
debated. For all of these reasons, a new
model is emerging, one with an extended
phase one that seeks from the beginning
to build upon preclinical information and
enrich trial populations for the genetic
marker of interest (Figure 1).
Changes in both method and expected
outcome do not come easily, either for
physicians or for pharmaceutical compa-
nies. The fragmentation of a market
among many subtypes of cancer, each
requiring a different treatment, means
the end of blockbuster compounds for
companies. However, it is worth noting
that a highly effective drug such as imati-
nib, administered daily for many years to
patients throughout the world, can stillprovide major financial returns to its
manufacturer. For clinicians, targeted
cancer therapy requires breaking down
traditional barriers in clinical medicine.
Phase one and novel drug testing teams
are no longer focused exclusively on
patients with advanced refractory
disease, irrespective of tumor character-
istics. Instead, early drug testing is being
integrated into the initial care of patients,
with the expressed goal of trying to match
the drug under study with specific
subsets of cancers, within a timeline that
may derive real benefit for patients partici-
pating in such trials.
Most importantly, the pathologist is now
in the critical position of going beyond the
standard histopathological diagnosis of
cancer, providing the oncologist with the
keybiomarkers that direct appropriate tar-
geted therapy. In some cases, this may
involve prescreening tumors to enable
a successful clinical trial. For example,
even for a common cancer, such as non-
small cell lung cancer, genotype-drug
combinations require testing a large
number of cases to enrich for EGFRmuta-
tions (10% of all cases), EML4-ALK rear-
rangements (4%), or MET, HER2, and
B-RAF abnormalities (1%–2% each). In
the landmark clinical trial of crizotinib
for EML4-ALK-translocated lung cancer,
1500 patients were prescreened to iden-
tify 82 cases with the translocation. These
patients were then selected for treatment
with crizotinib, producing benefit in 90%
of cases (57% responses and 33% stable
disease) (Kwak et al., 2010).
Despite dramatic initial responses in
genotype-selected clinical trials of epithe-
lial cancers and melanoma, acquired
resistance to targeted agents has
emerged as a primary challenge. We are
beginning only now to understand the
underlyingmechanisms of this resistance.
Some tumors acquire second-site muta-
tions in the target, which interferes with
drug binding (Kobayashi et al., 2005;
Pao et al., 2005; Talpaz et al., 2006),
whereas other tumors evolve alternative
signaling pathways, which compensate
for the disrupted oncogenic signal (Chan-
darlapaty et al., 2011; O’Reilly et al., 2006;
Tabernero et al., 2008). Achieving long-
lasting control of malignancy in this
setting may require sequential treatments
while monitoring the evolution of tumor
genotypes during therapy.
In some cases, signaling feedback
loops immediately activate alternative
pathways, which must be suppressed at
the outset by using a combination of tar-
geted therapies. For example, the initial
observation that mammalian target of
rapamycin (mTOR) inhibitors have limited
anticancer activity in the clinic resulted in
the identification of compensatory activa-
tion of insulin growth factor 1 receptor
(IGF-1R) when mTOR is blocked (O’Reilly
et al., 2006; Tabernero et al., 2008). This
led to a phase one clinical study in which
both mTOR and IGF-1R are inhibited.
Indeed, this combination treatment has
shown notable clinical efficacy in breast
cancer (Di Cosimo et al., 2010). Similarly,
the combined use of inhibitors against
the two critically important PI3K and
ERK pathways has shown remarkable
activity in preclinical models of cells
harboring K-RAS activating mutations
(Engelman et al., 2008). These and other
approaches that rationally combine thera-
pies are currently being explored in clin-
ical trials. Though very promising, these
trials may elicit a number of regulatory
challenges because they typically involve
the combined use of investigational
agents, each of which may have a sepa-
rate path to regulatory approval.
Innovative clinical trial platforms are
needed to address the opportunities and
challenges posed by the array of targeted
agents and their appropriate clinical
deployment. In addition to biomarkers
for preselection of responsive cancers,
early markers of clinical benefit are
needed to rapidly assess effectiveness
and inform ongoing monitoring of clinical
trials. The most promising approaches
include: repeat biopsies of tumor sites to
measure the impact of new therapies on
the degree of target inhibition; functional
tumor imaging through positron emis-
sions tomography (PET) or functional
magnetic resonance imaging (fMRI); and
molecular analysis of both genotypes
and signaling pathways within circulating
tumor cells in the blood (Maheswaran
et al., 2008). Together, these approaches
may provide early warnings of acquired
drug resistance and identify specific
resistance pathways that may direct the
choice of second line therapy (Figure 1).
Early tumor interrogation may also
result in a dynamic ‘‘real-time’’ measure-
ment of response or failure to the drugunder study, allowing for rapid adjust-
ments within clinical trial settings. For
example, in breast cancer, the testing of
new agents immediately prior to surgery
(known as ‘‘neo-adjuvant therapy’’) allows
for monitoring of tumor response at the
time of surgical resection. Compared to
the large number of patients and pro-
longed clinical follow-up required for
traditional postsurgery (or ‘‘adjuvant’’)
trials in breast cancer, neo-adjuvant trials
allow for rapid testing of multiple drug
combinations within small and affordable
trials. These new designs rely upon surro-
gate markers, such as changes in prolifer-
ation or apoptosis markers, or even
absence of visible tumor at the time of
surgery, which will then be correlated
with endpoints of clinical benefit, such
as time free of disease or improved overall
survival.
The Next Steps in the War
on Cancer
The War on Cancer has not been lost, nor
is it won. Instead, we are now at a turning
point, where fundamental knowledge
gathered over the past 40 years can, for
the first time, be applied directly to the
care of patients with cancer. Early results
in selected types of cancer are exciting in
themselves and in what they forecast for
the future of cancer treatment. However,
the rush for translational applications of
these initial breakthroughs should not be
interpreted as evidence that we now
know all we need to know about the path-
ogenesis, progression, and vulnerabilities
of cancer. Far from it, basic research in
cancer biology is progressing as never
before. New and unpredicted discoveries
continue to shed light on fundamental
mechanisms, from new insights into
long-studied genes like p53, to advances
that are transforming the fields of cancer
metabolism, chromatin regulation, and
noncoding RNA biology. There is still
much to discover, and continued support
for basic research is essential to continue
the progress in the War on Cancer.
Although the early successes in trans-
lating scientific discoveries into targeted
treatments are full of promise, they also
point to important future challenges. The
development of resistance by cancer
cells, even to the most dramatically effec-
tive therapies, underscores the need for
a detailed understanding of these resis-Cetance pathways. In addition, we need
tools to monitor the emergence of resis-
tance pathways in ‘‘real time’’ and new
generations of second line drugs to
suppress them. For the majority of
cancers, we still have not identified
molecular drivers as targets for treatment,
and common drivers, such as K-RAS, are
currently ‘‘undruggable.’’ Both of these
facts point to the need for further analyses
of genetic and epigenetic changes that
drive different cancers, as well as the
need for innovative approaches to drug
design. Finally, ‘‘smaller and smarter’’
clinical trials are necessary to rapidly
capitalize on credible therapeutic signals
and apply these to the treatment of early
cancers, for which major improvements
in long-term survival may be expected
(Smith et al., 2007).
Ironically, at this time of unparalleled
promise in cancer biology, the biggest
risk to progress may be economic.
Shrinking support for basic research
threatens the very foundation of the
success that we are now witnessing in
the clinic. Uncertainties in healthcare
delivery models may emphasize more
uniform and economical application of
the ‘‘standard of care,’’ prompting the
pharmaceutical industry and medical
community to shy away from developing
and testing innovative and initially expen-
sive new therapies. Public support and
enthusiasm are not enhanced by the
application of costly targeted therapies in
a nontargeted setting, where the measur-
able clinical impact is often marginal.
Despite these immediate and serious
concerns, we remain optimistic that the
next 10 years will witness unprecedented
progress in the fight against cancer, both
in terms of our fundamental under-
standing and direct clinical applications.
The extraordinary complexity of pathways
driving malignant proliferation may be
daunting, but the clinical impact of
a focused strategy targeted at suscep-
tible nodes within a cancer are compel-
ling. This is a time of exceptional promise
and a great reward for cancer
researchers. It comes none too soon for
patients with cancer.ACKNOWLEDGMENTS
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